Oncogenicity of PAKs and Their Substrates

PAKs, RAC/CDC42 (p21)-activated Kinases

Volumn , Issue , 2013, Pages 23-51

  He, Hong ^a   Maruta, Hiroshi ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NF TSC Cure Organisation   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882727908     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-407198-8.00002-3     Document Type: Chapter

References (162)

1. Hamilton SR Molecular genetics of colorectal carcinoma. Cancer 1992, 70:1216-1221.
2. Bos JL Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
3. Gibbs JB, Oliff A, Kohl NE Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77:175-178.
4. Downward J Ras signalling and apoptosis. Curr Opin Genet Dev 1998, 8:49-54.
5. Qiu RG, Chen J, Kirn D, McCormick F, Symons M An essential role for Rac in Ras transformation. Nature 1995, 374:457-459.
6. Qiu RG, Abo A, McCormick F, Symons M Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 1997, 17:3449-3458.
7. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 1994, 367:40-46.
8. Manser E, Leung T, Salihuddin H, Tan L, Lim L A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993, 363:364-367.
9. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs J, Chernoff J, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997, 17:4454-4464.
10. Tang Y, Marwaha S, Rutkowski J, Tennekoon G, Phillips P, Field J A role for Pak protein kinases in Schwann cell transformation. Proc Natl Acad Sci USA 1998, 95:5139-5144.
11. Nur-E-Kamal MSA, Kamal JM, Quresh MM, Maruta H The CDC42-specific inhibitor derived from ACK blocks the v-Ha-RAS-induced transformation. Oncogene 1999, 18:7787-7793.
12. Abercrombie M Contact inhibition: the phenomenon and its biological implications. Natl Cancer Inst Monogr 1967, 26:249-277.
13. Nwariaku F, Liu Z, Zhu X, Nahari D, Ingle C, Wu RF, et al. NADPH oxidase mediates vascular endothelial cadherin phosphorylation and endothelial dysfunction. Blood 2004, 104:3214-3220.
14. Xiao GH, Beeser A, Chernoff J, Testa JR PAK links Rac/Cdc42 signaling to Merlin. J Biol Chem 2002, 277:883-886.
15. Alfthan K, Heiska L, Grönholm M, Renkema G, Carpén.O PKA phosphorylates merlin at serine 518 independently of PAK and promotes merlin-ezrin hetero-dimerization. J Biol Chem 2004, 279:18559-18566.
16. He H, Levitzki A, Zhu HJ, Walker F, Burgess A, Maruta H Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 2001, 276:26741-26744.
17. Cifone MA In vitro growth characteristics associated with benign and metastatic variants of tumor cells. Cancer Metastasis Rev 1982, 1:335-347.
18. Yang S, Kim HM The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. Biomaterials 2012, 33:2902-2915.
19. del Pozo M, Price L, Alderson N, Ren XD, Schwartz M Adhesion to the extra-cellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000, 19:2008-2014.
20. Knowles H, Phillips R Identification of differentially expressed genes in experimental models of the tumor microenvironment using differential display. Anticancer Res 2001, 21:2305-2311.
21. Bagheri-Yarmand R, Vadlamudi R, Wang R, Mendelsohn J, Kumar R VEGF up-regulation via PAK1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000, 275:39451-39457.
22. Edwards D, Sanders L, Bokoch G, Gill G Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999, 1:253-259.
23. Dan C, Kelly A, Bernard O, Minden A Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem 2001, 276:32115-32121.
24. Yoshioka K, Foletta V, Bernard O, Itoh K A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003, 100:7247-7252.
25. Parsons D, Wang TL, Samuels Y, Bardelli A, Cummins J, DeLong L, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436:792.
26. Whale A, Dart A, Holt M, Jones G, Wells C PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene 2012, (in press).
27. Callow M, Clairvoyant F, Zhu S, Schryver B, Whyte D, Bischoff J, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002, 277:550-558.
28. Brown L, Kalloger S, Miller M, Shih Ie, M, McKinney S, Santos J, et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 2008, 47:481-489.
29. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007, 26:6997-7005.
30. Ong CC, Jubb A, Haverty P, Zhou W, Tran V, Truong T, et al. Targeting PAK1 to induce apoptosis of tumor cells. Proc Natl Acad Sci USA 2011, 108:7177-7182.
31. Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, et al. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther 2008, 7:1793-1802.
32. Reddy S, Ohshiro K, Rayala S, Kumar R MicroRNA-7, a homeobox D10 target, inhibits PAK 1 and regulates its functions. Cancer Res 2008, 68:8195-8200.
33. Hirokawa Y, Levitzki A, Lessene G, Baell J, et al. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 Drugs (Tyr-kinase inhibitors). Cancer Lett 2007, 245:242-251.
34. Demestre M, Messerli S, Celli N, Shahhossini M, et al. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res 2009, 23:226-230.
35. Maruta H An innovated approach to in vivo screening for the major anti-cancer drugs. Horizons in cancer research 2010, vol. 41. Nova Science Publishers, pp. 249-59.
36. Maruta H Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1. Drug Discov Ther 2011, 5:266-278.
37. Ying JE, Zhu LM, Liu BX Developments in metastatic pancreatic cancer: is gemcitabine still the standard?. World J Gastroenterol 2012, 18:736-745.
38. Kinzler K, Vogelstein B The colorectal cancer gene hunt: current findings. Hosp Pract (Off Ed) 1992, 27:51-58.
39. D'Abaco GM, Whitehead RH, Burgess AW Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas. Mol Cell Biol 1996, 16:884-891.
40. Hinds P, Finlay C, Levine A Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989, 63:739-746.
41. Easwaran V, Song V, Polakis P, Byers S The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling. J Biol Chem 1999, 274:16641-16645.
42. Zhu G, Wang Y, Huang B, Liang L, Ding Y, Xu A, et al. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 2012, 31:1001-1012.
43. Huynh N, Liu KH, Baldwin G, He H PAK 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta 2010, 1803:1106-1113.
44. He H, Huynh N, Liu K, Malcontenti-Wilson C, et al. PAK1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth. Cancer Lett 2012, 317:65-71.
45. Tetsu O, McCormick F Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
46. Grazia Lampugnani M, Zanetti A, Corada M, Takahashi T, Balconi G, Breviario F, et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol 2003, 161:793-804.
47. Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 2002, 99:14428-14433.
48. Baek HY, Lim JW, Kim H Interaction between the Helicobacter pylori CagA and alpha-Pix in gastric epithelial AGS cells. Ann NY Acad Sci 2007, 1096:18-23.
49. Murray B, Guo CX, Piraino J, Westwick J, et al. Small-molecule PAK inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci USA 2010, 107:9446-9451.
50. Balasenthil S, Sahin A, Barnes C, Wang R, Pestell R, Vadlamudi R, et al. PAK1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004, 279:1422-1428.
51. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006, 25:2931-2936.
52. Liu Y, Chen N, Cui X, Zheng X, Deng L, Price S, et al. Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis. Oncogene 2010, 29:5883-5894.
53. Wang RA, Mazumdar A, Vadlamudi R, Kumar R PAK1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 2002, 21:5437-5447.
54. Rayala S, Talukder A, Balasenthil S, Tharakan R, Barnes C, Wang RA, et al. PAK 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006, 66:694-701.
55. Shrestha Y, Schafer E, Boehm J, Thomas S, He F, Du J, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 2012, 31:3397-3408.
56. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One 2010, 5:e15940.
57. Friedland J, Lakins J, Kazanietz M, Chernoff J, Boettiger D, Weaver V α6β4 integrin activates Rac-dependent PAK1 to drive NFκB-dependent resistance to apoptosis in 3D mammary acini. J Cell Sci 2007, 120:3700-3712.
58. Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O Estrogen receptor-alpha phosphorylation at serine 305, nuclear PAK 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010, 16:1624-1633.
59. Nheu T, He H, Hirokawa Y, Walker F, Wood J, Maruta H PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell Cycle 2004, 3:71-74.
60. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, et al. Signal therapy of breast cancer xenograft in mice by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 2005, 4:956-960.
61. Aksamitiene E, Achanta S, Kolch W, Kholodenko B, Hoek J, Kiyatkin A Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI-3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal 2011, 23:1794-1805.
62. Tao J, Oladimeji P, Rider L, Diakonova M PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin. Mol Endocrinol 2011, 25:1565-1578.
63. Shalaby M, Shepard H, Presta L, Rodrigues M, Beverley P, Feldmann M, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992, 175:217-225.
64. Arias-Romero L, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy S, et al. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 2010, 29:5839-5849.
65. Pickl M, Ries C Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468.
66. zur Hausen H Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989, 49:4677-4681.
67. Chan JK, Berek JS Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007, 25:2975-2982.
68. Wu R, Abramson A, Symons M, Steinberg B Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. Int J Cancer 2010, 127:2230-2237.
69. Singh M, Singh N Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem 2011, 347:1-11.
70. Li J, Yen C, Liaw D, Podsypanina K, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 1943-1947.
71. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003, 66:897-906.
72. Suzuki H, Freije D, Nusskern D, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998, 58:204-209.
73. Sundram V, Chauhan S, Ebeling M, Jaggi M Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One 2012, 7:e35368.
74. Hirokawa Y, Tikoo A, Huynh J, Utermark T, et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004, 10:20-26.
75. Rodenhuis S, Slebos RJ The ras oncogenes in human lung cancer. Am Rev Respir Dis 1990, 142:S27-S30.
76. Kissil J, Walmsley M, Hanlon L, Haigis K, Bender Kim C, Sweet-Cordero A, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 2007, 67:8089-8094.
77. Brustugun O, Helland A, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, et al. Mutation testing for non-small-cell lung cancer. Tidsskr Nor Laegeforen 2012, 132:952-955.
78. Bianchi A, Mitsunaga S, Cheng JQ, Klein W, Jhanwar S, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995, 92:10854-10858.
79. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003, 163:985-992.
80. Hashimoto H, Sudo T, Maruta H, Nishimura R The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov Ther 2010, 4:1-4.
81. Hashimoto H, Messerli S, Sudo T, Maruta H Ivermectin inactivates the kinase PAK1 and block the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 2009, 3:243-246.
82. Porchia L, Guerra M, Wang YC, Zhang YL, et al. OSU-03012, a celecoxib derivative, directly targets PAK. Mol Pharmacol 2007, 72:1124-1131.
83. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004, 64:4309-4318.
84. Lee TX, Packer M, Huang J, Akhmametyeva E, Kulp S, Chen CS, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 2009, 45:1709-1720.
85. Stamenkovic I, Yu Q Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 2010, 11:471-484.
86. Bai LY, Weng JR, Tsai CH, Sargeant A, et al. OSU-03012 sensitizes TIB-196 myeloma cells to imanitib mesylate via AMPK and STAT3 pathways. Leuk Res 2010, 34:826-830.
87. Khan SB, Maududi T, Barton K, Ayers J, Alkan S Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004, 125:156-161.
88. Bharti A, Donato N, Singh S, Aggarwal B Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101:1053-1062.
89. Sawa H, Murakami H, Kumagai M, Nakasako M, et al. HDAC inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 2004, 107:523-531.
90. Kuo HC, Kuo WH, Lee YJ, Lee WL, et al. Bottom of form inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Lett 2006, 234:199-208.
91. Aoki H, Takada Y, Kondo S, Sawaya R, et al. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of AKT and ERK signaling pathways. Mol Pharmacol 2007, 72:29-39.
92. Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng.IO PAK is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving JNK activation and paxillin phosphorylation. Cancer Res 2007, 67:3601-3608.
93. Darvesh A, Aggarwal B, Bishayee A Curcumin and liver cancer: a review. Curr Pharm Biotechnol 2012, 13:218-228.
94. Pavey S, Zuidervaart W, van Nieuwpoort F, Packer L, Jager M, Gruis N, et al. Increased PAK-1 expression is associated with invasive potential in uveal melanoma. Melanoma Res 2006, 16:285-296.
95. Drinyaev V, Mosin V, Kluglyak E, Novik.T, et al. Antitumor effect of avermectin. Eur J Pharmacol 2004, 501:19-23.
96. Rennefahrt U, Deacon S, Parker S, Devarajan K, Beeser A, Chernoff J, et al. Specificity profiling of pak kinases allows identification of novel phosphorylation site. J Biol Chem 2007, 282:15667-15678.
97. Dummler B, Ohshiro K, Kumar R, Field J Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009, 28:51-63.
98. Shin EY, Shin KS, Lee CS, Woo KN, Quan SH, Soung NK, et al. Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem 2002, 277:44417-44430.
99. Foster D, Shen LH, Kelly J, Thibault P, Van Eyk J, Mak AS Phosphorylation of caldesmon by PAK. Implications for the Ca(2+) sensitivity of smooth muscle contraction. J Biol Chem 2000, 275:1959-1965.
100. McFawn P, Shen L, Vincent S, Mak A, Van Eyk J, Fisher J Calcium-independent contraction and sensitization of airway smooth muscle by PAK. Am J Physiol Lung Cell Mol Physiol 2003, 284:L863-L870.
101. 2+-independent contraction of smooth muscle. J Biol Chem 1998, 273:23433-23439.
102. Takizawa N, Koga Y, Ikebe M Phosphorylation of CPI17 and myosin binding subunit of type 1 protein phosphatase by PAK. Biochem Biophys Res Commun 2002, 297:773-778.
103. Vadlamudi R, Li F, Adam L, Nguyen D, Ohta Y, Stossel T, et al. Filamin is essential in actin cytoskeletal assembly mediated by PAK 1. Nat Cell Biol 2002, 4:681-690.
104. Zhao ZS, Lim JP, Ng YW, Lim L, Manser E The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell 2005, 20:237-249.
105. Sanders L, Matsumura F, Bokoch G, de Lanerolle P Inhibition of myosin light chain kinase by PAK. Science 1999, 283:2083-2085.
106. Goeckeler Z, Masaracchia R, Zeng Q, Chew TL, Gallagher P, Wysolmerski R Phosphorylation of myosin light chain kinase by PAK2. J Biol Chem 2000, 275:18366-18374.
107. Nguyen DG, Wolff K, Yin H, Caldwell J, et al. "UnPAKing" human immuno-deficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol 2006, 80:130-137.
108. Daub H, Gevaert K, Vandekerckhove J, Sobel A, Hall A Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem 2001, 276:1677-1680.
109. DerMardirossian C, Schnelzer A, Bokoch G Phosphorylation of RhoGDI by Pak1 mediates dissociation of Rac GTPase. Mol Cell 2004, 15:117-127.
110. Chew TL, Masaracchia R, Goeckeler Z, Wysolmerski R Phosphorylation of non-muscle myosin II regulatory light chain by p21-activated kinase (gamma-PAK). J Muscle Res Cell Motil 1998, 19:839-854.
111. Ramos E, Wysolmerski R, Masaracchia R Myosin phosphorylation by human cdc42-dependent S6/H4 kinase/gammaPAK from placenta and lymphoid cells. Recept Signal Transduct 1997, 7:99-110.
112. Goto H, Tanabe K, Manser E, Lim L, Yasui Y, Inagaki M Phosphorylation and reorganization of vimentin by PAK. Genes Cells 2002, 7:91-97.
113. Li QF, Spinelli A, Wang R, Anfinogenova Y, Singer H, Tang DD Critical role of vimentin phosphorylation at Ser-56 by p21-activated kinase in vimentin cytoskeleton signaling. J Biol Chem 2006, 281:34716-34724.
114. Tang DD, Bai Y, Gunst SJ Silencing of PAK attenuates vimentin phosphorylation on Ser-56 and reorientation of the vimentin network during stimulation of smooth muscle cells by 5-hydroxytryptamine. Biochem J 2005, 388:773-783.
115. Wang R, Li QF, Anfinogenova Y, Tang DD Dissociation of Crk-associated substrate from the vimentin network is regulated by PAK on ACh activation of airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007, 292:L240-L248.
116. Chan W, Kozma R, Yasui Y, Inagaki M, Leung T, Manser E, et al. Vimentin intermediate filament reorganization by Cdc42: involvement of PAK and p70 S6 kinase. Eur J Cell Biol 2002, 81:692-701.
117. Tran NH, Wu X, Frost J B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 2005, 280:16244-16253.
118. Huang Z, Traugh J, Bishop J Negative control of the Myc protein by the stress- responsive kinase Pak2. Mol Cell Biol 2004, 24:1582-1594.
119. Beeser A, Jaffer Z, Hofmann C, Chernoff J Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 2005, 280:36609-36615.
120. Tran NH, Frost J Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 2003, 278:11221-11226.
121. King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S, et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 1998, 396:180-183.
122. Wu X, Carr H, Dan I, Ruvolo P, Frost J PAK 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem 2008, 105:167-175.
123. Edin M, Juliano R Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor. Mol Cell Biol 2005, 25:4466-4475.
124. Chaudhary A, King W, Mattaliano M, Frost J, Diaz B, et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 2000, 10:551-554.
125. Zang M, Hayne C, Luo Z Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J Biol Chem 2002, 277:4395-4405.
126. Li Y, Shao Y, Tong Y, Shen T, et al. Nucleo-cytoplasmic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Biochim Biophys Acta 2012, 1823:465-475.
127. Park MH, Kim DJ, You ST, Lee CS, Kim HK, Park SM, et al. Phosphorylation of β-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun 2012, (in press).
128. Frost JA, Xu S, Hutchison M, Marcus S, Cobb M Actions of Rho family small G proteins and PAKs on mitogen-activated protein kinase family members. Mol Cell Biol 1996, 16:3707-3713.
129. Gallagher E, Xu S, Moomaw C, Slaughter C, Cobb M Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation. J Biol Chem 2002, 277:45785-45792.
130. Tuazon P, Lorenson M, Walker A, Traugh JA p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Lett 2002, 515:84-88.
131. Schurmann A, Mooney A, Sanders L, Sells M, Wang HG, Reed JC, et al. PAK1 phosphorylates the death agonist Bad and protects cells from apoptosis. Mol Cell Biol 2000, 20:453-461.
132. Jin S, Zhuo Y, Guo W, Field J PAK1-dependent phosphorylation of RAF-1 regulates its mitochondrial localization, phosphorylation of BAD, and BCL-2 association. J Biol Chem 2005, 280:24698-24705.
133. Ye DZ, Jin S, Zhuo Y, Field J Pak1 phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. PLoS One 2011, 6:e27637.
134. Jakobi R, Moertl E, Koeppel MA p21-activated protein kinase g-PAK suppresses programmed cell death of BALB3T3 fibroblasts. J Biol Chem 2001, 276:16624-16634.
135. Tang Y, Zhou H, Chen A, Pittman R, Field J The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem 2000, 275:9106-9109.
136. Vadlamudi R, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin A, et al. Dynein light chain 1, a PAK 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004, 5:575-585.
137. Mazumdar A, Kumar R Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 2003, 535:6-10.
138. Tuazon P, Spanos W, Gump E, Monnig C, Traugh J Determinants for substrate phosphorylation by p21-activated protein kinase (g-PAK). Biochemistry 1997, 36:16059-16064.
139. Fabian JR, Daar IO, Morrison DK Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 1993, 13:7170-7179.
140. Morin PJ Beta-catenin signaling and cancer. Bioessays 1999, 21:1021-1030.
141. Easwaran V, Song V, Polakis P, Byers.S The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling. J Biol Chem 1999, 274:16641-16645.
142. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 2005, 128:1907-1918.
143. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006, 281:9971-9976.
144. He H, Shulkes A, Baldwin GS PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins. Biochim Biophys Acta 2008, 1783:1943-1954.
145. He H, Huynh.N, Liu.K, Malcontenti-Wilson C, et al. PAK1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth. Cancer Lett 2012, 317:65-71.
146. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino M, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
147. Yau CY, Wheeler J, Sutton K, Hedley D Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI-3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005, 65:1497-1504.
148. Acconcia F, Barnes C, Singh R, Talukder A, Kumar R Phosphorylation-dependent regulation of nuclear localization and functions of integrin-linked kinase. Proc Natl Acad Sci USA 2007, 104:6782-6787.
149. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp S, et al. Identification and characterization of a novel ILK inhibitor. J Med Chem 2011, 54:6364-6374.
150. Hibi M, Lin A, Smeal T, Minden A, Karin M Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993, 7:2135-2148.
151. Bagrodia S, Dérijard B, Davis RJ, Cerione RA Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem 1995, 270:27995-27998.
152. Brown J, Stowers L, Baer M, Trejo J, Coughlin S, Chant J Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. Curr Biol 1996, 6:598-605.
153. Nheu T, He H, Hirokawa Y, Tamaki K, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 2002, 8:328-336.
154. Maroney A, Glicksman M, Basma A, Walton K, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998, 18:104-111.
155. Dan C, Nath N, Liberto M, Minden A PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol 2002, 22:567-577.
156. Ha UH, Lim JH, Kim HJ, Wu W, Jin S, Xu H, et al. MKP1 regulates the induction of MUC5AC mucin by Streptococcus pneumoniae pneumolysin by inhibiting the PAK4-JNK signaling pathway. J Biol Chem 2008, 283:30624-30631.
157. Cotteret S, Jaffer Z, Beeser A, Chernoff J Pak5 localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 2003, 23:5526-5539.
158. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001, 20:1940-1951.
159. Greer E, Dowlatshahi D, Banko M, Villen J, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol 2007, 17:1646-1656.
160. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek C, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001, 15:968-980.
161. Druker BJ Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
162. Kim EJ, Zalupski MM Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol 2011, 104:901-906.